Skip to main content
Premium Trial:

Request an Annual Quote

Xyris Appoints Kim as Chief Technical Officer

Premium

SAN DIEGO, Calif.--Xyris, the Axys Pharmaceuticals affiliate established earlier this year to apply the pharmaceutical company's proprietary bioinformatics and research technologies to the agriculture industry, has named Leo Kim as chief technical officer. Kim joined Xyris from Mycogen, where he had been responsible for worldwide research since 1986. In his new position he will oversee Xyris's research efforts. Prior to joining Mycogen, Kim was the highest ranking biotechnology scientist at Shell Development.

John Walker, Axys's CEO, commented, "Dr. Kim's knowledge and experience will have an immediate impact on the growth of Xyris and the implementation of Axys's technology platform."

Filed under

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.